The proceeds will be used to launch a new diagnostic instrument, a breast cancer monitoring assay, and proprietary multiplex immunofluorescence reagent kits.

The firm said that it slashed its GAAP EPS guidance and made a smaller cut to its non-GAAP EPS guidance in response to US tariffs and other geopolitical conditions.

The firm raised a total of $13.5 million in its Series A equity financing round, which will go toward growing and advancing its neurodegenerative disease testing business.

NEW YORK – Uppsala University spinout Readily Diagnostics is using technology built off 30 years of research as the basis of a point-of-care, instrument-free test that would detect and differentiate ...

Of the 30 companies on the list, 17 saw their stock prices decrease, 11 saw their share prices increase, and two had their stock prices remain flat.

NEW YORK – Eight German associations are calling for changes to be made to the European In Vitro Diagnostics Regulation (IVDR ...

The former True Health Diagnostics executives were accused of participating in a scheme that paid Texas physicians for blood test referrals.

NEW YORK – Molecular diagnostics firm EntroGen announced on Monday that its CRCdx RAS Mutation Detection Kit has received coverage from the US Centers for Medicare and Medicaid Services' MolDx program ...

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

Note: This story has been updated with comments from a conference call discussing the firm's financial results. NEW YORK – Revvity said Monday that it is making changes across its manufacturing, ...

NEW YORK — Digital pathology firm Gestalt Diagnostics said Monday that it has raised $7.5 million through a Series A financing round. The round was led by Cowles Ventures, TVF Funds, Inland Imaging ...

The company said that its test could overcome sensitivity issues with ultrasound and serum alpha-fetoprotein assays that are used to monitor at-risk patients.